503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25

📚 Book Relaunch: The book “Decoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy.
⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.
🔬 Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.
💊 PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.
📈 Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.
🏥 Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.
🎉 Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions